Drug-induced gastrointestinal damage: Part I – types and pathophysiological mechanisms of lesion)


DOI: https://dx.doi.org/10.18565/therapy.2020.6.171-183

Pereverzev A.P., Ostroumova O.D.

Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia, Moscow
The number of cases of drug-induced damage of the gastrointestinal tract (GIT) is increasing every year. Some of drugs like glucocorticosteroids, proton pump inhibitors, nonsteroidal anti-inflammatory drugs (NSAIDs) can damage several parts of the simultanesly.
Diagnostics of drug-induced gastrointestinal damage may be rather challenging due to the absence of specific symptoms and a huge number of various types (xerostomia, ulceration of the oral mucosa, dental caries, candidiasis, esophagitis, gastritis, enteritis, colitis, etc.) and insufficient knowledge of exact mechanisms (damage to the gastrointestinal tract as a consequence of the mechanism of drug action, violation of the integrity of the mucous membrane, direct damaging effect, changes in the microbiota, etc.) of lesion.
Keywords: enteropathy, rebamipid, colopathy, adverse reactions, esophagitis, gastropathy, gastrointestinal tract, drugs
Read entire article

Literature


  1. Information resource «statista.com». Available at: https://www.statista.com (date of access – 30.06.2020).

  2. Global Medicines Use in 2020: Outlook and Implications. Available at: https://www.iqvia.com/-/media/iqvia/pdfs/institute-reports/global-medicines-use-in-2020 (date of access – 30.06.2020).

  3. Fernandes D.C.R., Norman A.J. Drug-induced gastrointestinal disorders. Medicine. 2019; 47(5): 301–08. doi: https://doi.org/10.1016/j.mpmed.2019.02.010.

  4. https://www.fda.gov (date of access – 30.06.2020).

  5. Jain V., Pitchumoni C.S. Gastrointestinal side effects of prescription medications in the older adult. J Clin Gastroenterol. 2009; 43: 103–10. doi: 10.1097/MCG.0b013e31818f9227.

  6. Zentler-Munro P.L., Northfield T.C. Drug-induced gastrointestinal disease. Br Med J. 1979; 1: 1263–65.

  7. Scarpignato C., Bjarnason I. Drug-Induced Small Bowel Injury: a Challenging and Often Forgotten Clinical Condition. Curr Gastroenterol Rep. 2019; 21(11): 55. doi:10.1007/s11894-019-0726-1.

  8. Philpott H.L., Nandurkar S., Lubel J., Gibson P.R. Drug-induced gastrointestinal disorders. Frontline Gastroenterology. 2014; 5(1): 49–57. doi: 10.1136/flgastro-2013-100316.

  9. Cotton B.R., Smith G. The lower oesophageal sphincter and anaesthesia. Br J Anaesth. 1984; 56(1): 37–46.

  10. Tutuian R., Clinical Lead Outpatient Services and Gastrointestinal Function Laboratory. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol. 2010; 24(2); 91–97. doi: 10.1016/j.bpg.2010.02.005.

  11. Godara N., Godara R., Khullar M. Impact of inhalation therapy on oral health. Lung India. 2011; 28(4): 272–75. doi:10.4103/0970-2113.85689.

  12. https://emedicine.medscape.com/article/1080772-overview (date of access – 02.06.2020)

  13. Ramirez Martinez-Acitores L., Hernandez Ruiz de Azcarate F., Casanas E. et al. Xerostomia and aalivary flow in patients taking antihypertensive drugs. Int J Environ Res Public Health. 2020; 17(7): 2478. doi:10.3390/ijerph17072478.

  14. Marginean E.C. The ever-changing landscape of drug-induced injury of the lower gastrointestinal tract. Arch Pathol Lab Med. 2016; 140(8): 748–58. doi:10.5858/arpa.2015-0451-RA.

  15. Bonavina L., DeMeester T.R., McChesney L. et al. Drug-induced esophageal strictures. Ann Surg. 1987;206(2): 173–83. doi: 10.1097/00000658-198708000-00010.

  16. Переверзев А.П., Остроумова О.Д., Ткачева О.Н., Кочетков А.И. Лекарственно-индуцированная дисфагия у лиц пожилого и старческого возраста. Доказательная гастроэнтерология. 2020; 1: 32–40. [Pereverzev A.P., Ostroumova O.D., Tkacheva O.N., Kochetkov A.I. Drug-induced dysphagia in elderly patients. Dokazatel'naya gastroenterologiya. 2020; 1: 32–40 (In Russ.)]. doi: 10.17116/dokgastro2020901132.

  17. Остроумова О.Д., Переверзев А.П., Краснов Г.С. Возможные нежелательные побочные реакции ингибиторов протонной помпы у больных пожилого и старческого возраста. Лечебное дело. 2018; 4: 7–17. [Ostroumova O.D., Pereverzev A.P., Krasnov G.S. Possible adverse effects of proton pump inhibitors in elderly and senile patients. Lechebnoe delo. 2018; 4: 7–17 (In Russ.)]. doi: 10.24411/2071-5315-2018-12060.

  18. Остроумова О.Д., Голобородова И.В., Исаев Р.И., Переверзев А.П. Антипсихотики: особенности нежелательных побочных реакций у лиц пожилого и старческого возраста. Журнал неврологии и психиатрии им. C.C. Корсакова. 2019; 2: 105–117. [Ostroumova O.D., Goloborodova I.V., Isaev R.I., Pereverzev A.P. Antipsychotics: features of undesirable adverse reactions in elderly and senile age. Zhurnal nevrologii i psikhiatrii im. S.S. Korsakova. 2019; 2: 105–117 (In Russ.)]. doi: 10.17116/jnevro2019119021105.

  19. Переверзев А.П., Ткачева О.Н., Котовская Ю.В., Остроумова О.Д. Синдром недостаточности питания у пожилых пациентов как осложнение лекарственной терапии – взгляд клинического фармаколога. Безопасность и риск фармакотерапии. 2019; 1: 23–30. [Pereverzev A.P., Tkacheva O.N., Kotovskaya Y.V., Ostroumova O.D. Malnutrition in elderly patients as a complication of a drug therapy: clinical pharmacologist’s point of view. Bezopasnost' i risk farmakoterapii. 2019; 1: 23–30 (In Russ.)]. doi: 10.30895/2312-7821-2019-7-1-23-30.

  20. Переверзев А.П., Остроумова О.Д., Ткачева О.Н., Котовская Ю.В. Осложнения фармакотерапии новыми оральными антикоагулянтами, вызванные межлекарственным взаимодействием: акцент на желудочно-кишечные кровотечения. Безопасность и риск фармакотерапии. 2019; 2: 65–71. [Pereverzev A.P., Ostroumova O.D., Tkacheva O.N., Kotovskaya Yu.V. Complications of pharmacotherapy with new oral anticoagulants caused by inter-drug interactions: focus on gastrointestinal bleeding. Bezopasnost' i risk farmakoterapii. 2019; 2: 65–71 (In Russ.)]. doi: 10.30895/2312-7821-2019-7-2-65-71.

  21. No authors listed. Drugs that promote dental caries. Prescrire Int. 2015; 24(157): 41-44.

  22. De Campaigno E.A.P., Kebir I., Montastruc J.L. et al. Drug-Induced Dental Caries: A Disproportionality Analysis Using Data from VigiBase [published correction appears in Drug Saf. 2018 May 8]. Drug Saf. 2017; 40(12): 1249-58. doi:10.1007/s40264-017-0575-5.

  23. Patil S., Rao R.S., Majumdar B., Anil S. Clinical Appearance of Oral Candida Infection and Therapeutic Strategies. Front Microbiol. 2015; 6: 1391. doi:10.3389/fmicb.2015.01391.

  24. Porter S.R., Scully C. Oral malodour (halitosis). BMJ. 2006; 333(7569): 632-35. doi:10.1136/bmj.38954.631968.AE.

  25. M. Torsten G., Gomez-Moreno A., Aguilar-Salvatierra A. Drug-related oral malodour (halitosis): a literature review. Eur Rev Med Pharmacol Sci. 2017; 21(21): 4930-34.

  26. Tungare S., Paranjpe A.G. Drug Induced Gingival Overgrowth (DIGO) [Updated 2019 Dec 20]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan. Available at: https://www.ncbi.nlm.nih.gov/books/NBK538518/ (date of access – 30.06.2020)

  27. Bharti V., Bansal C. Drug-induced gingival overgrowth: The nemesis of gingiva unravelled. J Indian Soc Periodontol. 2013; 17(2): 182-87. doi:10.4103/0972-124X.113066

  28. Severe drug-induced gingival enlargement and periodontitis: A case series with clinical presentation and management. Available at: https://pocketdentistry.com/severe-drug-induced-gingival-enlargement-and-periodontitis-a-case-series-with-clinical-presentation-and-management (date of access – 02.06.2020)

  29. Doty R.L., Shah M., Bromley S.M. Drug-induced taste disorders. Drug Saf. 2008; 31(3): 199-215. doi:10.2165/00002018-200831030-00002.

  30. Dag M.S., Ozturk Z.A., Akın I. et al. Drug-induced esophageal ulcers: case series and the review of the literature. Turk J Gastroenterol. 2014; 25(2): 180-84. doi:10.5152/tjg.2014.5415.

  31. Hayashi Y., Yamamoto H., Kita H. et al. Non-steroidal anti-inflammatory drug-induced small bowel injuries identified by double-balloon endoscopy. World J Gastroenterol. 2005; 11(31): 4861-64. doi:10.3748/wjg.v11.i31.4861.

  32. Geramizadeh B., Taghavi A., Banan B. Clinical, endoscopic and pathologic spectrum of non-steroidal anti-inflammatory drug-induced colitis. Indian J Gastroenterol. 2009: 28(4): 150–53. doi: 10.1007/s12664-009-0053-9.

  33. Brechmann T., Gunther K., Neid M. et al. Triggers of histologically suspected drug-induced colitis. World J Gastroenterol. 2019; 25(8): 967-79. doi: 10.3748/wjg.v25.i8.967.

  34. So H.F., Bloomfield I. Small bowel obstruction due to non-steroidal anti-inflammatory drug-induced diaphragm disease: A case report. Cureus. 2018; 10(3): e2350. doi:10.7759/cureus.2350.

  35. Coolsen M., Leedham S.J., Guy R.J. Non-steroidal anti-inflammatory drug-induced diaphragm disease: an uncommon cause of small bowel obstruction. Ann R Coll Surg Engl. 2016; 98(8): e189-e191. doi:10.1308/rcsann.2016.0235.

  36. George C.F. Drugs causing intestinal obstruction: a review. J R Soc Med. 1980; 73(3): 200-04.

  37. Dall M., Schaffalitzky de Muckadell O.B., Lassen A.T., Hallas J. There is an association between selective serotonin reuptake inhibitor use and uncomplicated peptic ulcers: a population-based case-control study. Aliment Pharmacol Ther. 2010; 32(11-12): 1383-91. doi: 10.1111/j.1365-2036.2010.04472.x.

  38. Poitras R., Warren D., Oyogoa S. Opioid drugs and stercoral perforation of the colon: Case report and review of literature. Int J Surg Case Rep. 2018; 42: 94-97. doi: 10.1016/j.ijscr.2017.11.060.

  39. Sliesoraitis S., Tawfik B. Bevacizumab-induced bowel perforation. J Am Osteopath Assoc. 2011; 111(7): 437-41.

  40. Anglin R., Yuan Y., Moayyedi P. et al. Risk of upper gastrointestinal bleeding with selective serotonin reuptake inhibitors with or without concurrent nonsteroidal anti-inflammatory use: a systematic review and meta-analysis. Am J Gastroenterol. 2014; 109(6): 811-19. doi: 10.1038/ajg.2014.82.

  41. Haagsma E.B., Hagens V.E., Schaapveld M. et al. Increased cancer risk after liver transplantation: a population-based study. J Hepatol. 2001; 34(1): 84-91. doi: 10.1016/s0168-8278(00)00077-5.

  42. King G.N., Healy C.M., Glover M.T. et al. Increased prevalence of dysplastic and malignant lip lesions in renal-transplant recipients. N Engl J Med. 1995; 332(16): 1052-57. doi: 10.1056/NEJM199504203321602.

  43. Hernandez G., Arriba L., Jimenez C. et al. Rapid progression from oral leukoplakia to carcinoma in an immunosuppressed liver transplant recipient. Oral Oncol. 2003; 39(1): 87-90. doi: 10.1016/s1368-8375(02)00009-x.

  44. Brusselaers N., Engstrand L., Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018; 53: 172-77. doi: 10.1016/j.canep.2018.02.004.

  45. Paz M.F.C.J., de Alencar M.V.O.B., de Lima R.M.P. et al. Pharmacological Effects and Toxicogenetic Impacts of Omeprazole: Genomic Instability and Cancer. Oxid Med Cell Longev. 2020; 2020: 3457890. doi: 10.1155/2020/3457890.

  46. Tran T.H., Li H. Olmesartan and drug-induced enteropathy. P T. 2014; 39(1): 47-50.

  47. Mancano M.A. Ranolazine-Induced reversible t-wave inversions with prolonged QTc interval; progressive multifocal leukoencephalopathy linked to fingolimod; losartan-induced sprue-like enteropathy; nivolumab-induced psoriasiform skin eruption; hepatitis B reactivation with hepatitis C Treatment with simeprevir and sofosbuvir. Hosp Pharm. 2015; 50(11): 965-68. doi: 10.1310/hpj5011-965.

  48. Kamal A., Fain C., Park A. et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019; 7(3): 162-67. doi:10.1093/gastro/goz019.

  49. Craft A.W., Kay H., Lawson D.N., McElwain T.J. Methotrexate-induced malabsorption in children with acute lymphoblastic leukaemia. Br Med J. 1977; 2(6101): 1511-12. doi: 10.1136/bmj.2.6101.1511.

  50. Wolfe D., Kanji S., Yazdi F. et al. Drug induced pancreatitis: A systematic review of case reports to determine potential drug associations. PLoS One. 2020; 15(4): e0231883. doi: 10.1371/journal.pone.0231883.

  51. Brusselaers, N., Sadr-Azodi O., Engstrand, L. Long-term proton pump inhibitor usage and the association with pancreatic cancer in Sweden. J Gastroenterol. 2020; 55, 453–61. doi: 10.1007/s00535-019-01652-z.

  52. Dubeau M.F., Iacucci M., Beck P.L. et al. Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis. 2013; 19(2): 445-56. doi: 10.1002/ibd.22990.

  53. Maekawa T., Ohji G., Inoue R. et al. Pill-induced esophagitis caused by lansoprazole. J Gastroenterol. 2001; 36(11): 790-91. doi: 10.1007/s005350170024.

  54. Chiba M/, Sugawara T/, Tozawa H/ et al. Lansoprazole-associated collagenous colitis: diffuse mucosal cloudiness mimicking ulcerative colitis. World J Gastroenterol. 2009; 15(17): 2166-69. doi:10.3748/wjg.15.2166.

  55. Brusselaers N., Lagergren J., Engstrand L. Duration of use of proton pump inhibitors and the risk of gastric and oesophageal cancer. Cancer Epidemiol. 2019; 62: 101585. doi: 10.1016/j.canep.2019.101585.

  56. Brusselaers N., Engstrand L, Lagergren J. Maintenance proton pump inhibition therapy and risk of oesophageal cancer. Cancer Epidemiol. 2018; 53: 172-77. doi: 10.1016/j.canep.2018.02.004.

  57. Международная база данных нежелательных реакций Сотрудничающего центра по мониторингу лекарственных средств Всемирной организации здравоохранения (WHO-UMC) и Всемирной организации здравоохранения (WHO) «VigiAccess». URL: www.vigiaccess.org (дата обращения – 30.06.2020). [Electronic tools database of the Collaborating Center for Monitoring International Medicines of WHO-UMC and WHO «VigiAccess». URL: www.vigiaccess.org (date of access – 30.06.2020) (In Russ.)].

  58. Mohamed A.A., Lu X.L., Mounmin F.A. Diagnosis and Treatment of Esophageal Candidiasis: Current Updates. Can J Gastroenterol Hepatol. 2019; 2019: 3585136. doi: 10.1155/2019/3585136.

  59. Nassar Y., Eljabbour T., Lee H., Batool A. Possible Risk Factors for Candida Esophagitis in Immunocompetent Individuals. Gastroenterology Res. 2018; 11(3): 195-99. doi: 10.14740/gr1019w.

  60. Cotton B.R., Smith G. The lower oesophageal sphincter and anaesthesia. Br J Anaesth: 1984, 56(1); 37-46.

  61. Tutuian R, Clinical lead outpatient services and gastrointestinal function laboratory. Adverse effects of drugs on the esophagus. Best Pract Res Clin Gastroenterol: 2010, 24(2); 91-97. doi: 10.1016/j.bpg.2010.02.005.

  62. Scarpignato C., Gatta L., Zullo A., Blandizzi C.; SIF-AIGO-FIMMG Group; Italian Society of Pharmacology, the Italian Association of Hospital Gastroenterologists, and the Italian Federation of General Practitioners. Effective and safe proton pump inhibitor therapy in acid-related diseases – A position paper addressing benefits and potential harms of acid suppression. BMC Med. 2016; 14(1): 179. doi:10.1186/s12916-016-0718-z.

  63. Ивашкин В.Т., Шептулин А.А., Маев И.В. с соавт. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению эрозивно- язвенных поражений желудка и двенадцатиперстной кишки, вызванных нестероидными противовоспалительными препаратами. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2014; 6: 89-94. [Ivashkin V.T., Sheptulin A.A., Maev I.V. et al. Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of erosive and ulcerative lesions of the stomach and duodenum caused by non-steroidal anti-inflammatory drugs. Rossiysky zhurnal gastroenterologii, gepatologii, koloproktologii. 2014; 6: 89-94 (In Russ.)].

  64. Лазебник Л.Б., Голованова Е.В., Алексеенко СА. с соавт. Рекомендации по профилактике и лечению эзофаго-гастро-энтеро-колопатий, индуцированных нестероидными противовоспалительными препаратами (НПВП). Доступ: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2018/КЛАССИФИКАЦИЯ%20Л.ЛАЗЕБНИК.%20Г.БЕЛОВА%20ДЛЯ%20УТВЕРЖДЕНИЯ%20НА%20КОНГРЕССЕ.pdf (дата обращения – 09.06.2020). [Lazebnik L.B., Golovanova E.V., Alekseenko S.A. et al. Recommendations for the prevention and treatment of esophago-gastro-enterocolopathies induced by nonsteroidal anti-inflammatory drugs (NSAIDs). URL: https://www.rnmot.ru/public/uploads/RNMOT/clinical/2018/КЛАССИФИКАЦИЯ%20Л.ЛАЗЕБНИК.%20Г.БЕЛОВА%20ДЛЯ%20УТВЕРЖДЕНИЯ%20НА%20КОНГРЕССЕ.pdf (date of access – 09.06.2020) (In Russ.)].

  65. Государственный реестр лекарственных средств Минздрава России. Доступ: http://grls.rosminzdrav.ru. (дата обращения – 09.06.2020). [State Register of Medicines of the Ministry of Health of Russia. URL: http://grls.rosminzdrav.ru. (date of access – 09.06.2020).

  66. Zeino Z., Sisson G., Bjarnason I. Adverse effects of drugs on small intestine and colon. Best Pract Res Clin Gastroenterol. 2010; 24: 133–41. doi: 10.1016/j.bpg.2010.02.008.

  67. Davies N.M. Sustained release and enteric coated NSAIDs: are they really GI safe? J Pharm Pharm Sci. 1999; 2(1): 5-14.

  68. Свистунов А.А., Осадчук М.А., Киреева Н.В. с соавт. НПВП-индуцированная энтеропатия: современное состояние проблемы. Терапевтический архив. 2018; 8: 95-100. [Svistunov A.A., Osadchuk M.A., Kireeva N.V. et al. NSAID-induced enteropathy: the current state of the problem. Terapevtichesky arkhiv. 2018; 8: 95-100 (In Russ.)]. doi: 10.26442/terarkh201890895-100.

  69. Kamal A., Fain C., Park A. et al. Angiotensin II receptor blockers and gastrointestinal adverse events of resembling sprue-like enteropathy: a systematic review. Gastroenterol Rep (Oxf). 2019; 7(3): 162-67. doi: 10.1093/gastro/goz019.

  70. Burbure N., Lebwohl B., Arguelles-Grande C. et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human Pathology. 2016; 50: 127-34. doi: 10.1016/j.humpath.2015.12.001.

  71. Choi E.K., McKenna B.J. Olmesartan-associated enteropathy: A review of clinical and histological findings. Archives Of Pathology Lab Medicine. 2015; 139: 1242-47. doi: 10.5858/arpa.2015-0204-RA.

  72. Marietta E.V., Cartee A., Rishi A. et al. Drug-induced enteropathy. Dig Dis. 2015; 33: 215–20. doi: 10.1159/000370205.

  73. Mazhar A., Arnautovic J. An unusual cause of diarrhea: losartan-induced sprue-like enteropathy, Am J of Gastroenterology. 2017; 112: S1320-S1321.

  74. Freeman H.J. Olmesartan Enteropathy. Int J of Celiac Disease. 2016; 4(1):24-26. doi: 10.12691/ijcd-4-1-6.

  75. de Fonseka A., Tuskey A., Moskalul C. A case of olmesartan-induced enteropathy. Inflamm Bowel Dis. 2012; 18: S17.

  76. Rubio-Tapia A., Hermann M.L., Ludvigsson J.F. et al. Severe spruelike enteropathy associated with olmesartan. Mayo Clin Proc. 2012; 87(8): 732-38. doi: 10.1016/j.mayocp.2012.06.003..

  77. Talbot G.H. Small bowel histopathologic findings suggestive of celiac disease in an asymptomatic patient receiving olmesartan. Mayo Clin Proc. 2012; 87: 1231-1232. doi: 10.1016/j.mayocp.2012.09.011.

  78. Basson M., Mezzarobba M., Weill A. et al. Severe intestinal malabsorption associated with olmesartan: a French nationwide observational cohort study [published online Aug 6 2015]. Gut 2015. http://dx.doi.org/10.1136/gutjnl-2015-309690.

  79. Burbure N., Lebwohl B., Arguelles-Grande C. et al. Olmesartan-associated sprue-like enteropathy: a systematic review with emphasis on histopathology. Human Pathology. 2016; 50:127–34. doi: 10.1016/j.humpath.2015.12.001.

  80. Narietta E.V., Nadeau A.M., Cartee A.K. et al. Immunopathogenesis of olmesartan-associated enteropathy. Aliment Pharmacol Ther. 2015; 42: 1303-14. doi: 10.1111/apt.13413.

  81. Tanner A.R., Raghunath A.S. Colonic inflammation and nonsteroidal anti-inflammatory drug administration. An assessment of the frequency of the problem. Digestion. 1988; 41(2): 116-20. doi: 10.1159/000199740.

  82. Bakshi R., Ezzet N., Frey L. et al. Efficacy and tolerability of diclofenac dispersible in painful osteoarthrosis. Clin Rheumatol. Clin Rheumatol. 1993; 12(1): 57-61. doi: 10.1007/BF02231560.

  83. Hamdeh S., Micic D., Hanauer S. Drug-induced colitis. Clin Gastroenterol Hepatol. 2020; S1542-3565(20)30614-5. doi: 10.1016/j.cgh.2020.04.069.

  84. Маев И.В., Кучерявый Ю.А., Андреев Д.Н., Черемушкин С.В. Эволюция представлений о микроскопическом колите. Терапевтический архив. 2015; 4: 69-76. [Maev I.V., Kucheryavyi Yu.A., Andreev D.N., Cheremushkin S.V. Evolution of ideas on microscopic colitis. Terapevtichesky arkhiv. 2015; 4: 69-76 (In Russ.)]. doi: 10.17116/terarkh201587469-76.

  85. Gentile N.M., Khanna S., Loftus E.V. Jr et al. The epidemiology of microscopic colitis in Olmsted County from 2002 to 2010: a population-based study. Clin Gastroenterol Hepatol. 2014; 1 (5): 838-42. doi: 10.1016/j.cgh.2013.09.066.

  86. Vigren L., Olesen M., Benoni C., Sjoberg K. An epidemiological study of collagenous colitis in southern Sweden from 2001-2010. World J Gastroenterol. 2012; 18 (22): 2821-26. doi: 10.3748/wjg.v18.i22.2821.

  87. Beaugerie L., Pardi D.S. Review article: drug-induced microscopic colitis - proposal for a scoring system and review of the literature. Aliment Pharmacol Ther. 2005; 22: 277-84. doi: 10.1111/j.1365-2036.2005.02561.x.

  88. Thomson R.D., Lestina L.S., Bensen S.P. et al. Lansoprazole-associated microscopic colitis: a case series. Am J Gastroenterol. 2002; 97: 2908-13. doi: 10.1111/j.1572-0241.2002.07066.x.

  89. Mukherjee S. Diarrhea associated with lansoprazole. J Gastroen-terol Hepatol. 2003; 18: 602-03. doi: 10.1046/j.1440-1746.2003.02801.x.

  90. Chagnon J.P., Cerf M. Simvastatin-induced protein-losing enteropathy. Am J Gastroenterol 1992; 87: 257.

  91. Duncan H.D., Talbot 1.С., Silk D.B.A. Collagenous colitis and ci- metidine. Eur J Gastroenterol Hepatol. 1997; 9: 819-20.

  92. Fernandez-Banares F., Esteve M., Espinos J.C. et al. Drug consumption and the risk of microscopic colitis. Am J Gastroenterol. 2007; 102: 324-30. doi: 10.1111/j.1572-0241.2006.00902.x.

  93. Fernandez-Banares F., de Sousa M.R., Salas A. et al. Epidemiological risk factors in microscopic colitis: a prospective case-control study. Inflamm Bowel Dis. 2013; 19: 411-17. doi: 10.1002/ibd.23009.

  94. Keszthelyi D., Penders J., Masclee A.A., Pierik M. Is microscopic colitis a drug-induced disease? J Clin Gastroenterol 2012; 46: 811-22. doi: 10.1097/MCG.0b013e3182618506.

  95. Crockett S.D., Porter C.Q., Martin C.F. et al. Isotretinoin use and the risk of inflammatory bowel disease: a case–control study. Am J Gastroenterol. 2010; 105: 1986–93. doi: 10.1038/ajg.2010.124.

  96. Cornish J.A., Tan E., Simillis C. et al. The risk of oral contraceptives in the etiology of inflammatory bowel disease: a meta-analysis. Am J Gastroenterol. 2008;103: 2394–400. doi: 10.1111/j.1572-0241.2008.02064.x.

  97. Звенигородская Л.А., Самсонова Н.Г., Парфенов А.И., Хомерики С.Г. Клинико-функциональные и морфологические изменения толстой кишки у больных с хронической абдоминальной ишемией. Экспериментальная и клиническая гастроэнтерология. 2008; 6: 9-13. [Zvenigorodskaya L.A., Samsonova N.G., Parfenov A.I., Khomeriki S.G. Clinical, functional and morphological changes in the colon in patients with chronic abdominal ischemia. Eksperimental'naya i klinicheskaya gastroenterologiya. 2008; 6: 9-13 (In Russ.)].

  98. FitzGerald J.F., Hernandez III L.O. Ischemic colitis. Clinics in colon and rectal surgery. 2015; 28(2): 93-98. doi: 10.1055/s-0035-1549099.

  99. Nikolic A.L., Keck J.O. Ischaemic colitis: uncertainty in diagnosis, pathophysiology and management. ANZ J Surg. 2018; 88(4): 278-83. doi:10.1111/ans.14237.

  100. Безносов Н.С., Шурова Т.И., Корниенко Т.Г. соавт. Синдром хронической абдоминальной ишемии как диагностическая проблема. Архивъ внутренней медицины. 2015; 2: 65-68. [Beznosov N.S., Shurova T.I., Kornienko T.G. et al. Chronic abdominal ischemia syndrome as a diagnostic problem. Arkhiv vnutrenney meditsiny. 2015; 2: 65-68 (In Russ.)].

  101. Ойноткинова О.Ш., Белякин С.А., Мироненко Д.А. Дифференциальные подходы к диагностике хронической абдоминальной ишемии. Архивъ внутренней медицины. 2011; 2: 64-68. [Oynotkinova O.Sh., Belyakin S.A., Mironenko D.A. Differential approaches to the diagnosis of chronic abdominal ischemia. Arkhiv vnutrenney meditsiny. 2011; 2: 64-68 (In Russ.)].

  102. Сайт Государственного Научного центра Колопроктологии и Ассоциации Колопроктологов России. Доступ: http://www.gnck.ru (дата обращения – 30.06.2020). [URL: http://www.gnck.ru (date of access – 30.06.2020) (In Russ.)].

  103. Шелыгин Ю.А., Алешкин В.А., Сухина М.А. с соавт. Клинические рекомендации национальной ассоциации специалистов по контролю инфекций, связанных с оказанием медицинской помощи и общероссийской общественной некоммерческой организации «Ассоциации колопроктологов россии» по диагностике, лечению и профилактике Clostridium difficile-ассоциированной диареи (CDI). Доступ: http://www.gnck.ru/rec/recommendation_clostridium_difficile.pdf (дата обращения 30.06.2020). [Shelygin Yu.A., Aleshkin V.A., Sukhina M.A. et al. Clinical guidelines of the national association of specialists in the control of infections associated with the provision of medical care and the all-Russian public non-profit organization «Association of Coloproctologists of Russia» for the diagnosis, treatment and prevention of Clostridium difficile-associated diarrhea (CDI). URL: http://www.gnck.ru/rec/recommendation_clostridium_difficile.pdf (date of access – 30.06.2020) (In Russ.)].

  104. Jones M.R., Hall O.M., Kaye A.M., Kaye A.D. Drug-induced acute pancreatitis: a review. Ochsner J. 2015; 15(1): 45–51.

  105. Российское общество хирургов. Национальные клинические рекомендации по острому панкреатиту. Доступ: http://общество-хирургов.рф/stranica-pravlenija/unkr/urgentnaja-abdominalnaja-hirurgija/nacionalnye-klinicheskie-rekomendaci-po-ostromu-pankreatitu.html (дата обращения: 09.06.2020). [Russian Society of Surgeons. National clinical practice guidelines for acute pancreatitis. Available at: http://общество-хирургов.рф/stranica-pravlenija/unkr/urgentnaja-abdominalnaja-hirurgija/nacionalnye-klinicheskie-rekomendaci-po-ostromu-pankreatitu.html (date of access – 09.06.2020) (In Russ.)].


About the Autors

Anton P. Pereverzev, PhD, associate professor of the Department of therapy and polymorbid pathology of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia. Address: 125993, Moscow, 2/1 build 1 Barrikadnaya Str. Tel.: +7 (916) 538-87-81. E-mail: acchirurg@mail.ru. ORCID: 0000-0001-7168-3636. ESPIN: 4842-3770
Olga D. Ostoumova, MD, professor, head of the Department of therapy and polymorbid pathology of Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of Russia. Address: 125993, Moscow, 2/1 build 1 Barrikadnaya Str. Tel.: +7 (903) 169-68-28. E-mail: ostroumova.olga@mail.ru. ORCID: 0000-0002-0795-8225. ESPIN: 3910-6585


Similar Articles

Back to Content

Бионика Медиа